Shawn E Green

US Patent:

6518298, Feb 11, 2003

Filed:

Feb 20, 2001

Appl. No.:

09/788872

Inventors:

Shawn J. Green - Vienna VA
Jamshed H. Shah - Columbia MD
John Madsen - Knoxville MD
Robert J. DAmato - Cambridge MA

Assignee:

Entremed, Inc. - Rockville MD

International Classification:

A61K 3140

US Classification:

514416

Abstract:

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.

US Patent:

6593291, Jul 15, 2003

Filed:

Oct 14, 1999

Appl. No.:

09/418546

Inventors:

Shawn J. Green - Vienna VA

Assignee:

EntreMed, Inc. - Rockville MD

International Classification:

A01N 3718

US Classification:

514 2, 514 21, 435 71, 530350, 530300

Abstract:

Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise naturally occurring, or synthetic proteins, peptides, or protein fragments capable of binding to components of the blood coagulation pathway. The compositions may be administered using a pharmaceutically acceptable carrier. The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized metastasized tumors is useful for preventing the growth or expansion of such tumors.

US Patent:

6605622, Aug 12, 2003

Filed:

May 25, 2001

Appl. No.:

09/866279

Inventors:

Shawn J. Green - Vienna VA

Assignee:

EntreMed, Inc. - Rockville MD

International Classification:

A61K 31445

US Classification:

514324

Abstract:

The present invention provides compounds that are useful for inhibiting the proliferation of fungi. The compounds are estrogenic derivatives, such as 2ME2, or anti-estrogenic compounds. The compounds may be used for treating infections of fungi in humans and animals, or to prevent or inhibit the growth of fungi on any surface.

US Patent:

6673828, Jan 6, 2004

Filed:

May 11, 1999

Appl. No.:

09/309464

Inventors:

Shawn J. Green - Vienna VA
Jamshed H. Shah - Columbia MD
John Madsen - Knoxville MD
William Fogler - Rockville MD

Assignee:

Childrens Medical Center Corporation - Boston MA

International Classification:

A61K 314035

US Classification:

514416, 548472

Abstract:

The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(-)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.

US Patent:

6734163, May 11, 2004

Filed:

Jan 22, 2001

Appl. No.:

09/766778

Inventors:

Shawn J. Green - Vienna VA

Assignee:

EntreMed, Inc. - Rockville MD

International Classification:

A61K 3855

US Classification:

514 2, 514 12

Abstract:

Compositions and methods for inhibiting cellular proliferation wherein the composition contains Tissue Factor Pathway Inhibitor (TFPI), a TFPI homolog, or an active fragment thereof. TFPI exhibits potent anti-proliferative activity on human and other animal cells, particularly endothelial cells. More particularly, the TFPI, TFPI homolog, and inhibitory fragment thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.

US Patent:

6773669, Aug 10, 2004

Filed:

Nov 8, 2000

Appl. No.:

09/707928

Inventors:

John W. Holaday - Bethesda MD
Peter H. Meserol - Montville NJ
Doug Doerfler - Darnestown MD
Shawn J. Green - Vienna VA
Vininder Singh - Gaithersburg MD

Assignee:

Maxcyte, Inc. - Rockville MD

International Classification:

C12N 1587

US Classification:

422 44, 422 33, 4351736

Abstract:

The present invention relates to a method and apparatus for the encapsulation of substances and drugs into cells and platelets. The present invention is also related to the incorporation of thrombus dissolving drugs, such as tissue plasminogen activator and streptokinase into platelets using the apparatus described herein. The treated platelets can then be used to treat patients suffering from a thrombus blocking a blood vessel. The present invention is also related to a preparation of red blood cells that has a stable right shift of the oxygen dissociation curve.

US Patent:

6946439, Sep 20, 2005

Filed:

Feb 28, 2002

Appl. No.:

10/086176

Inventors:

Todd Hembrough - Damascus MD, US
Victor P. Pribluda - Silver Spring MD, US
Shawn J. Green - Vienna VA, US

Assignee:

Entre Med, Inc. - Rockville MD

International Classification:

A61K038/16

US Classification:

514 2, 514 12, 514 13

Abstract:

Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of the C-terminal portion of proteinase inhibitors such as TFPI. The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.

US Patent:

6995278, Feb 7, 2006

Filed:

Feb 8, 2001

Appl. No.:

09/779331

Inventors:

Gregory E. Agoston - Germantown MD, US
Victor Pribluda - Silver Spring MD, US
Anthony M. Treston - Rockville MD, US
Shawn J. Green - Vienna VA, US

Assignee:

Entre Med, Inc. - Rockville MD

International Classification:

A61K 31/56
C07J 41/00
C07J 1/00

US Classification:

552614, 552518, 552519, 552522, 552625, 552626, 552627, 514182

Abstract:

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.